Introduction:
The pharmaceutical industry in Japan has been experiencing significant growth over the past few years, with a focus on biologics and biosimilars. In 2020, the market size of biologics in Japan was estimated to be around $4.5 billion, with a projected annual growth rate of 8.5%. This growth is driven by an aging population and the increasing prevalence of chronic diseases. In this report, we will explore the top 10 biologics and biosimilars companies in Japan for the year 2026.
Top 10 Biologics & Biosimilars Companies in Japan 2026:
1. Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd. is a leading biopharmaceutical company in Japan, specializing in the development of innovative biologics. With a market share of 25% in the biologics sector, Chugai has been a key player in the industry, with a focus on oncology and autoimmune diseases.
2. Daiichi Sankyo Co., Ltd.
Daiichi Sankyo Co., Ltd. is another major player in the biologics and biosimilars market in Japan, with a strong presence in cardiovascular and oncology therapies. The company holds a market share of 20% and has been investing heavily in research and development to expand its product portfolio.
3. Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Japan. With a market share of 15%, Takeda is known for its innovative biologics and biosimilars targeting rare diseases and gastrointestinal disorders.
4. Astellas Pharma Inc.
Astellas Pharma Inc. is a leading pharmaceutical company in Japan, with a focus on urology, oncology, and transplantation. The company has a market share of 10% in the biologics and biosimilars sector and has been expanding its presence in the global market through strategic partnerships.
5. Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based pharmaceutical company in Japan, with a strong focus on neurology and oncology. With a market share of 8%, Eisai has been at the forefront of developing innovative biologics and biosimilars for various therapeutic areas.
6. Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd. is a specialty pharmaceutical company in Japan, with a market share of 7% in the biologics and biosimilars market. The company focuses on rare diseases, oncology, and immunology, and has been expanding its global presence through strategic collaborations.
7. Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd. is a global healthcare company based in Japan, known for its innovative biologics and biosimilars in the areas of mental health and nephrology. With a market share of 6%, Otsuka has been investing in research and development to address unmet medical needs.
8. Shionogi & Co., Ltd.
Shionogi & Co., Ltd. is a pharmaceutical company in Japan, with a market share of 5% in the biologics and biosimilars sector. The company focuses on infectious diseases, pain management, and women’s health, and has been expanding its product portfolio through strategic acquisitions.
9. Meiji Seika Pharma Co., Ltd.
Meiji Seika Pharma Co., Ltd. is a leading pharmaceutical company in Japan, with a market share of 4% in the biologics and biosimilars market. The company specializes in diabetes, infectious diseases, and allergies, and has been investing in research and development to drive innovation.
10. Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation is a research-based pharmaceutical company in Japan, with a market share of 3% in the biologics and biosimilars sector. The company focuses on autoimmune diseases, respiratory disorders, and neurology, and has been expanding its global presence through strategic partnerships.
Insights:
The biologics and biosimilars market in Japan is expected to continue its growth trajectory in the coming years, driven by an aging population and the increasing prevalence of chronic diseases. By 2026, the market size of biologics in Japan is projected to reach $6.5 billion, with a compound annual growth rate of 9%. Key trends to watch out for include an increase in collaborations between domestic and international companies, as well as a focus on personalized medicine and precision therapies. Overall, the top 10 biologics and biosimilars companies in Japan are well-positioned to capitalize on these opportunities and drive innovation in the industry.
Related Analysis: View Previous Industry Report
